Agenus to Showcase Initial Phase 2 Botensilimab Results in Advanced Cutaneous Melanoma at ASCO 2026 Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company focused on developing next-generation cancer immunotherapies, announced today that four scientific abstracts featuring its lead checkpoint inhibitor…
Speak Foundation Introduces Patient-Led National LGMD Centers of Excellence to Drive Clinical Trials and Innovative Treatments Speak Foundation has announced the launch of a major new initiative aimed at transforming care delivery and accelerating therapeutic development for patients living with…
RareCyte Broadens Clinical-Scale Spatial Proteomics Offering with New Orion Systems and Leadership Addition RareCyte has announced a major expansion of its spatial proteomics capabilities, marking a strategic step forward in its mission to advance biomarker-driven research and precision medicine. The…
Synthetic Design Lab reveals first logic-gated ADC at AACR 2026 with ≥10x enhanced targeted cancer cell killing Synthetic Design Lab, an emerging innovator in the field of antibody-drug conjugates (ADCs) and advanced protein engineering, has unveiled compelling preclinical findings that…
Zai Lab reports strong, rapid brain metastasis responses with Zocilurtatug Pelitecan in SCLC and other neuroendocrine cancers Zai Lab Limited has unveiled compelling new clinical and preclinical data highlighting the potential of its oncology pipeline, led by zocilurtatug pelitecan (zoci,…
Onchilles Pharma Presents at AACR 2026 New Preclinical Data from the Systemically Delivered NEU-002 Program, Supporting Advancement Toward Development Candidate Selection Onchilles Pharma, a privately held biotechnology company focused on advancing next-generation cancer therapeutics targeting the ELANE pathway, has unveiled…
Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026 At the ESCMID Global 2026, the Microbiology & Infection Diagnostics division of Bruker Corporation unveiled a major advancement in molecular diagnostics with the European launch of the MyGenius PRO.…
Nucleai and Sirona Dx Partner to Deliver an Integrated Spatial Proteomics Solution for Pharma Drug Development Nucleai, a leader in AI-powered spatial biology analytics, and Sirona Dx, a Technical CRO, specialized in spatial biology and single-cell services, today announced a…
Quanterix Debuts Content Innovation Engine at AACR 2026 Quanterix Corporation today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeting 2026. Built on the integration of Akoya Biosciences’ spatial biology platform…
Forlong Biotechnology Announced CMC Readiness to Initiate GMP Batch Production to Support Upcoming Pivotal Clinical Trial for FL115 (IL-15 Superagonist) in Nonmuscle Invasive Bladder Cancer (NMIBC) Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients…
Astellas Doses First Patient in Phase 3 Study of setidegrasib (ASP3082) for KRAS G12D-mutated Metastatic Pancreatic Ductal Adenocarcinoma Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the first patient has been successfully dosed in the Phase…
VectorBuilder Introduces High-Stability MuteFree™ AAV to Improve Gene Therapy Manufacturing Reliability VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a high-stability AAV vector designed to address ITR instability, a common challenge in gene…